About Us
  Join the Mailing List

Agenda/ Speakers

Exhibit/ Sponsorship Opportunities


Hotel Accommodation


Conference Handbook


GeneExpression Systems, Inc & Appasani Research Conferences and Educational Institute (ARCEI.ORG)
Jointly Presents

Precision Medicine Symposia USA - 2016
RNAi to Genome Editing by CRISPRs &Optogenetics to Antibody Technology

RNAi/MicroRNAs to Stem Cells & Genome Editing – 2016 Meeting

On ‘RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering’
5th International
Neuron to Synapse & Optogenetics – 2016 Meeting

On ‘Neuronal Function to Mapping & Brain Disease Therapeutics’
First International
Structural Biology to Ubiquitin/Antibodies & Protein Machines-2016 Meeting
   On ‘Proteases, Proteasomes to Small & Large Molecules for Disease Biology’


Venue: Hilton Garden Inn Boston/Burlington
5 Wheeler Road, Burlington, Massachusetts, 01803 USA

MAY 4 – 5, 2016


Expected Maximum Capacity of each Meeting
Target Audience 100
Total Speaker Presentations: 30
Total Poster Presentations: 10
Total Exhibit Booths: 10

Click Here For Agenda

Wednesday, May 4, 2016
8:00 AM: Registration Open
8:30 AM - 6:30PM Scientific Sessions

Thursday, May 5, 2016
8:00 A.M: Registration Open
8:30 AM - 6:00PM Scientific Sessions

The purpose and scope of this Precision Medicine Symposia USA - 2016 (on May 4-5, 2016) is to provide a forum for the discussion of the current state of the art of rapidly evolving RNA interference, MicroRNAs, Stem Cells, Genome Editing; Structure and Therapeutic Biology of Proteases, Ubiquitin, Antibodies; and Network biology of Brain Mapping and Optogenetics methods to study neurodevelopmental and neuropsychological diseases. Most of these themes are highly interdisciplinary emerging fields in biotechnology. This will consists of three parallel theme meetings:

1. RNA interference to CRISPR Interference (RNAi/MicroRNAs/Stem Cells & Genome Editing)-2016 Meeting: This is our 13th international theme conference continuously held in the first week of May in the Greater Boston area, Massachusetts, USA. Emeritus Professor Arthur Pardee of the Harvard University Medical School inaugurated our first meeting in May 2003. Since then, pioneers in both RNAi/MicroRNAs/Stem Cells fields including: Nobel laureates Drs. Craig Mello (UMass Med), Richard Roberts (NEBiolabs), Elizabeth Balckburn (UCSF), Paul Berg (Stanford), and Professors Gary Ruvkun (Harvard), David Bartel (MIT), Carlo Croce (OSU), Irving Weissman (Stanford), Kevin Eggan (Harvard), Harvey Lodish (MIT), James Collins (BU) and Chad Cowan (MGH)and many more have given keynote speeches. RNAi/MicroRNAs/Stem Cells were the “biology’s Big Bang from 2000-2010” and we ignited the spirit of both  RNomics&microRNomics& Stem Cells in order to understand the biology of gene-silencing and Reprogramming. CRISPR Interference and Endonuclease-based Genome engineering and editing is the “big-bang of the present decade 2010 – 2020”. Thus, we launched knowledge-transfer meetings in this area in order to develop innovative products based on this new technology platforms.

2. Neuron to Synapse & Optogenetics-2016: This is our 4th international theme conference to be held on May 4-5, 2016 in Greater Boston area. In the past, pioneers in Neuroscience and Neurology fields including: Nobel laureate Eric Kandel (Columbia), Robert Horvitz (MIT); and Drs. Robert Darnell (Rockefeller), Joseph LeDoux (NYU), Joshua Sanes (Harvard), AntonelloBonci (NIH), Joan Fallon (Curemark) and many more have given keynote speeches. In recent years there is a great trend emerging in understanding the biology of neuron to synapses and their defects in memory, learning and cognition. Specially, to decipher the ‘Brain Code and Mapping’ novel technique such as Optogenetics has been adopted to study connectomics and to develop brain-interface devices to treat several neurodegenerative/neuro psychotic diseases. Therefore, this meeting will focus on the disease biology of neuro/synaptic disorders and how one can fix these problems with optogenetics and how to develop novel drug targets using this technology platform.

3. Structural Biology to Ubiquitin/Antibodies & Protein Machines-2016: This year we are inaugurating a new theme meeting to cover the Structural biology of Proteases, Enzymes, membrane Proteins and protein machineries including Ribosomes, Ubiquitin and Antibodies. Additionally this meeting will also cover the mechanisms of ubiquitin mediated signaling pathways in stem cells and various human diseases, and novel technology platforms to generate antibodies for drug development. In this international meeting, prominent researchers (Developmental biologists, cell biologists, geneticists, molecular biologists, computational biologists, structural biologists, neurobiologists, clinicians, chemists and physicists)  from both academia and industry will gather and discuss the applications in form of keynote lectures, invited talks, short oral, and poster presentations.
These meetings are open for graduate students, postdoctoral fellows and professors from academia and research scientists and executives from bio-pharma industry to gain insights in the emerging frontiers in biotechnology.

Venue: Hilton Garden Inn Boston/Burlington is a star hotel located on the high-tech corridor on Route 95/128, which has easy access from Airport and Boston/Cambridge Downtown areas and few miles away from the world renowned Massachusetts Institute of Technology and Harvard University Campuses. This venue is also few miles away from the Biotech hub of University Park and Pharmaceutical giants such as: Novartis, Pfizer, Amgen and Takeda.

Note: All the members (except keynote speakers and others who arranged with organizer) who participate in this symposium have to register for the meeting by paying the appropriate registration fee.

Scientific Organizer:

Krishnarao Appasani, PhD, MBA
Founder & CEO
GeneExpression Systems, Inc
Waltham, MA USA




Edward Scolnick, MD.
Founder of Stanley Center for Psychiatric Research &                               
Professor of the Practice in Biology, Broad Inst. of MIT and Harvard
& Former CEO of Merck
Cambridge, MA, USA
Title: Neuro-genetics of Psychiatric diseases
Jeffrey D. Parvin, MD, PhD.
Louis Levy Professor for Cancer                              
Associate Dean for Graduate Studies &
The Ohio State University
Columbus, OH, USA
Title: Bookmark Ubiquitination
Frank Slack, PhD.
Professor of Pathology &                                          
Director, Institute for RNA Medicine
BIDMC Cancer Center/Harvard Medical School
Boston, MA, USA
Title: MicroRNA-based therapeutics in cancer

Dennis J. Selkoe, MD.
The Vincent and Stella Coates Professor of Neurologic Diseases 
Harvard Medical School&
Co-Director, Ann Romney Center for Neurologic Diseases                         
Brigham and Women's Hospital
Boston MA, USA
Title: Molecular Elucidation of Alzheimer’s and Parkinson’s Diseases Predicts Novel Therapies

Tod Woolf, PhD.                                                                  
Chief Executive Officer
Etagen Pharma Inc.
Cambridge, MA, USA
Title: Chemically-modified polynucleotides for inhibiting, expressing and repairing nucleic acids

Daniel G. Anderson, PhD.
Samuel A. Goldblith Professor of Applied Biology& Chemical Engg.
Harvard-MIT Division of Health Sciences & Technology
David H. Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Cambridge, MA, USA
Title: Nucleic acid delivery systems for RNA therapy and gene editing

Other Speakers:
RNAi/Stem Cells & Editing Neuron & Optogenetics and Structural Biology Antibodies/Ubiquitin
Erik Sontheimer, PhD.
University of Massachusetts Medical School,
Worcester, MA, USA
Title: Neisseria meningitidisCas9 is a naturally high-fidelity genome editing enzyme
Sharath Sriram, PhD.    
Associate Professor
RMIT University
Melbourne, Victoria, Australia
Title: Memristors: Bio-inspired synpase-like electronic memories
David J. FitzGerald, PhD.
Sr. Investigator
National Cancer Institute-NIH
Bethesda, MD, USA
Title: A whole genome RNAi screen highlights components of the ER/Golgi as a prominent source of resistance to immunotoxin-mediated cytotoxicity
Christa J. van Dort, PhD.
Instructor, MIT & Massachusetts General Hospital
Cambridge, MA, USA
Title: Characterization and Control of the Neural Circuits Involved in Sleep Regulation

Mark W. Feinberg, MD.
Associate Professor of Medicine
Brigham and Women's Hospital/Harvard Medical School
Boston, MA, USA
Title: MicroRNA-mediated control of glucose homeostasis and insulin resistance

Michael Strano, PhD.
Professorof Chemical Engg.
Massachusetts Institute of Technology
Cambridge, MA, USA
Title: Emerging applications of carbon nanosensortechnology to precision medicine

Richard L. Frock, PhD.
Harvard Medical School
Boston MA, USA
Title: Breaking Bad: Genome-wide detection of designer Nuclease targeting and its ensuing collateral damage
Alan D. D'Andrea, MD.     
The Fuller-American Cancer Society Professor
Harvard Medical School
Boston, MA, USA
Title: Targeting Ubiquitin pathways in cancer therapy

 Kexian Zhu, PhD. candidate
Stem Cell and Regenerative Biology
Harvard University
Cambridge, MA, USA
Title: Gene editing in dystrophic mouse muscle and muscle stem cells

Andrey Kovalevsky, PhD.
R&D Scientist
Oak Ridge National Laboratory
Oak Ridge, TN, USA
Title: Neutron crystallographic studies of HIV-1 protease: Drug binding, drug resistance and proton transfer

Gerald Marsischky, PhD. 
Director, Genome Engineering Production Group
Harvard Medical School
Boston MA, USA
Title:CRISPR/Cas9-based genome editing strategies in Drosophila, Human cells and mouse germlines

Dongming Cai, MD, PhD.
Assistant Professor of Neurology
Icahn (Mount Sinai) School Of Medicine 
New York, NY, USA
Title: Apo-E4 associated Alzheimer disease pathogenesis

Cecilia Cotta-Ramusino, PhD.Senior Scientist
Editas Medicine, Inc.
Cambridge, MA, USA
Title: Effect of different CRISPR/Cas9 variants on repair pathway choices

Dianne Hoffman-Kim, PhD.
Associate Professor of Medical Science
Brown Inst for Neuroscience
Brown University
Providence, RI, USA
Title: 3D Neural Spheroid Culture: An In Vitro Model for Cortical Studies

Victor Dillard                                    
Chief Operating officer
Desktop Genetics Ltd.
London, United
Bioinformatic tools to design genome editing experiments using CRISPR/Cas9 system Kingdom

Jonathan P. Newman, PhD.
ostdoctoral Fellow
Massachusetts Institute of Technology
Cambridge, MA, USA
Title:Real-time optical feedback to control and study neural dynamics

Cheryl H. Cui, PhD. candidate
Harvard-MIT Div. of Health Sci. & Tech.
Massachusetts Institute of Technology
Cambridge, MA, USA
Title: Massively parallel combinatorial genetic perturbation screening with CRISPR-Cas9 in human cells

Oleg A. Sineshchekov, PhD.
Research Professor of Biochemistry
Univ. of Texas Health Science Center
Houston TX,USA
Title: Anion channelrhodopsins from cryptophyte algae as new efficient tools for inhibitory optogenetics

Yvonne Tay, PhD.
Assistant Professorof Biochemistry
Yong Lo Lin School of Medicine
National University of Singapore, Singapore
Title: MicroRNA-638 regulates iron metabolism in prostate cancer

Alexander Serganov, Ph.D.
Assistant Professor of Biochemistry
New York University School of Medicine
New York, NY, USA
Title: Role of RNA-protein interactions in gene expression control 

Raffaella Sordella, PhD.
Associate Professor
Cold Spring Harbor Laboratory Cancer Center
Cold Spring Harbor, NY, USA
Title: CRISPR-based Genome Editing

Amar Sahay, PhD.
Assistant Professor of Psychiatry
Harvard’s Massachusetts General Hospital, Boston, MA, USA
Title: Adult hippocampal neurogenesis and fear generalization

Miguel A. Moreno-Mateos PhD.
Associate Research Scientist in Genetics
Yale University School of Medicine
New Haven, CT, USA
Title: Applying an optimized CRISPR/Cas9 system to uncover genes involved in brain development

Tomas J. Ryan, PhD.     
HHMI Research Specialist
Picower INST. for Learning and Memory
Massachusetts Institute of Technology
Cambridge, MA, USA
Title: Precise manipulation of memory using engram cell technology

Chengyu Jiang, PhD.
Professor of Biochemistry
Peking Union Medical College&CAS
Beijing, P.R. China
Title: MicroRNAs role in Ebola virus infection

Xiaohong Zhang, PhD.
Associate Professorof
University of South Florida
Tampa, FL, USA
Title: HDAC6 as a deacetylase and E3 ligase

Padmanabh (Pad) Chivukula PhD.
Founder & Chief Scientific Officer
Arcturus Therapeutics, Inc.
San Diego, CA, USA
Title: TBA


Bruno Combettes, PhD.                              
Business Development Manager EMEA
Andor technology PLC.
Belfast, United Kingdom
Title: TBA

James L. Sherley, MD., PhD.
Director Asymmetrex, LLC.
Boston, MA, USA
Title: Bringing precision to gene-editing therapeutics by counting hematopoietic stem cells

Richie Kohman, PhD.          
Biomaterials Engineer& Group Leader
Expansion Technologies Inc.
Cambridge, MA, USA
Title: Light-initiated release of neurotransmitters from DNA nanostructures

Dong-ki Lee, Ph. D.                          
Professor of Chemistry
Sungkyunkwan University, Suwon,&
Founder and CEO
OliX Pharmaceuticals, Seoul, SouthKorea


Xue Jun (June) Li, PhD.
Associate Professorof Biomedical Sciences
University of Illinois
Rockford, IL, USA
Title: Elucidating the degeneration of spinal motor neurons in human models of spinal muscular atrophy


Andrew Grimson, PhD.
Assistant Professor of Molecular Biology and Genetics
Cornell University,
Ithaca, NY, USA
Title: Fetal and adult progenitors give rise to unique populations of CD8+ T cells


Jiannis Ragoussis, PhD.
Professor and Head of Genome Sciences
McGill University
Montréal, Québec, Canada
Title: Comprehensive mir-210 target identification reveals new prognostic markers in breast cancer


Junjun Shi, PhD.
Assistant Professor of Anesthesia
Brigham and Women’s Hospital
Boston MA, USA,
Title: RNAi Nanotechnology for cancer target validation and therapy


Leonid A. Pobezinsky, PhD.
Assistant Professor of Vet. & Animal Sciences, University of Massachusetts
Amherst, MA, USA
Title: Regulatory role of non-coding RNAs in immune responses

Patrick Y. Lu, PhD                  
President & CEO
Sirnaomics, Inc.
Gaithersburg, MD 20879, USA
Title: Development of three generations of nanoparticles for novel siRNA therapeutics 

Dong-Wook Kim (DW Kim), PhD.
Professor of Physiology
Yonsei University College of Medicine
Seoul, South Korea 
Title: Genome Editing of Structural Variations in Patient-derived iPS Cells




* Presenting Speaker names, title and times are subject to change.
Host organization, organizer, or scientific committee does not take any kind of responsibility.

Key Topics:
RNAi/Stem Cells & Editing Neuron & Optogenetics Structural Biology Antibodies/Ubiquitin
  • RNAi Interference to CRISPR Interference
  • Biology of RNAi, MicroRNAs, NcRNAs,&Stem Cells
  • Molecular Mechanisms of Endonucleases (TALENs, ZFNs, CRISPRs)
  • Self-renewal, Pluripotency& Reprogramming of Stem Cells
  • Disease Biology of RNAi/miRNAs and Endonucleases
  • Generation of CRISPRs/ZFN/TALEN-mediated knockout animals and cell lines
  • RNAi/siRNA/MicroRNA in vivo/in vitro delivery methods
  • Biopolymer Applications in Stem Cell Therapy &Tissue Engineering
  • Genome Editing/Genome-wide Screeningstowards Synthetic Biology & Precision Medicine
  • Drug/Therapeutic Development using RNAi, microRNAs/NcRNAs and CRISPRs
  • Neural plasticity & Synapse Connectomics, Cognition & Behavior
  • Neurobiology of Autism, Epilepsy, Schizophrenia, Alzheimer’s & Other Diseases
  • Biochemistry of light-mediated Opsin proteins & Gated channels
  • Development & Targeting optogenetic tools in vivo and in vitro
  • Mapping memory engrams & Imaging of neuronal circuits and networks
  • Crystallography, Microscopy & Spectroscopy of optogenetic molecules
  • Optogenetics applications in Stem Cell/Cardiac & Disease Biology
  • Drug/Therapeutic Development for Neurodegenerative Diseases
  • Optogenetics in Vision, Memory, Plasticity & Sleep
  • Optogenetics to Probe Neurodegenerative and Psychiatric disorders
  • Structures of Proteases, Enzymes, Membrane Proteins and Ribosomes
  • Antibody Engineering by Novel Technology& Synthetic Antibodies
  • Ubiquitin Proteasome Systems, Signalosome-mediated Proteolysis
  • Molecular Modeling for Structure Prediction & Determination
  • CART-based Immunotherapy and Antibodies as Drugs for Disease Biology
  • UPS/ULPs in Stem Cell Growth & Reprogramming
  • X-Ray Diffraction, NMR &Cryo-Electron Microscopy Techniques
  • UPS in Disease Biology (Allergy, Inflammation, Autophagy, Innate Immunity, Cancer etc). 
  • Synthesis of Small & Large Molecules for Drug Discovery
  • UPS/ULPs-based Drug Target Discovery for Therapy & Biomarkers/Diagnostics


Exhibitors are welcome to reserve their booth space early!

Please contact if you are interested in speaking in the scientific or Technology workshops of this meeting.

GeneExpression Systems, Inc.
P.O. Box 540170
Waltham, MA 02454 USA
Tel: (781) 891-8181
Fax: (781)730-0700 or (781) 891-8234
E-mail: Genexpsys@expressgenes.com

Note: Speakers Names, Titles and venue subjected to change beyond our control for which the company is not responsible.

Oral Presentation Submission by March 10, 2016
Poster Abstract Submission by April 20, 2016

Email your abstract (100-200 words in word format) to: genexpsys@expressgenes.com

GeneExpression Systems™ All Rights Reserved 2016